Figure 2
From: Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis
Axial T2 weighted and coronal STIR MRI images of the proximal left arm at baseline (a and b) and following 11 months of pazopanib (c and d). A large focus of fibromatosis expands the triceps muscle and following 11 months of treatment reduced in size from 10.2 cm in maximum craniocaudal dimension to 8.0 cm. Predominantly intermediate/high signal tissue (a and b, arrows) showed a marked reduction in signal (c and d, arrows) indicating diminished cellularity.